|Videos|September 20, 2016

Tuberculosis Prevalence in the US

John D'Angelo, MD, senior vice president, executive director Emergency Medicine Services at Northwell Health, discusses the prevalence of tuberculosis in the United States.

John D'Angelo, MD, senior vice president, executive director Emergency Medicine Services at Northwell Health, discusses the prevalence of tuberculosis (TB) in the United States.

Interview Transcript (slightly modified for readability)

“Most people that are now newly diagnosed with TB, which is much less common to be newly diagnosed nowadays, but we still have immigrant populations and other ways that people can get exposed, just go on multiple drugs at this point; usually it’s a three-drug regimen at minimal, for a 6-month period of time or longer.

I think [that] overall, the TB rate, at least in our country, is dramatically reduced from years ago, [due to] active screening, the precautions that are taken when we cough, [as well as other] precautions that occur in the hospital, and [the fact that] all of our employees get a [purified protein derivative] PPD test annually. I think it’s difficult to treat when it’s found, but it’s not as devastating as it was in the past when it was rampant and you had disseminated TB and things of that nature; we just don’t see it in the emergency department that often.”


Related to this article

Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.